ABT-737
Senolytic Bcl2 inhibitor / Inhibitor of anti-apoptotic proteins from the Bcl family: Bcl-2, Bcl-X(L), and Bcl-w (Ki < 1 nM) that causes regression of solid tumors in mice.1 Senolytic agent which disrupts aberrant p21 expression, inducing apoptosis in senescent cells, and enhancing liver regeneration in mice.2,3 Acts synergistically to reduce cell viability when combined with CDK inhibitor purvalanol A in preclinical models of acute myeloid leukemia (AML).4
Biochemicals & reagents
852808-04-9
1 Oltersdorf et al. (2005), An inhibitor of Bcl-2 family proteins induces regression of solid tumors; Nature, 435 677 2 Yosef et al. (2016), Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL; Nat. Commun., 7 11190 3 Ritschka et al. (2020), The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice; Genes Dev., 34 489 4 Lappin et al. (2020), A compound combination screening approach with the potential to identify new treatment options for paediatric acute myeloid leukaemia; Sci. Rep., 10 18514
-20°C
TARGET: Bcl-2 -- PATHWAY: Mitochondrial function; Apoptosis inducer; Senescence; Bcl -- RESEARCH AREA: Cell death; Neuroscience -- DISEASE AREA: Cancer; AgeingNeurodegeneration